Skip to main content

Table 2 Background characteristics of patients by bleeding status on antithrombotic group

From: The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection

  Bleeding (n = 21) Non-bleeding (n = 69) p value
Age(yr) 65.4 ± 13.4 64.7 ± 13.8 0.838
Gender (M/F)(%M) 12/9(57.1) 42/27(60.9) 0.760
H. pylori infection(+/−)(%positive) 17/4(81.0) 56/13(81.2) 0.983
Tumor size(mm) 15.8 ± 6.1 15.7 ± 5.4 0.942
Tumor type IIa 11 40 0.411
IIa + IIc 2 12
IIc 8 17
Ulcerative scars in the tumor(+/−)(%positive) 5/16(23.8) 16/53(23.2) 0.953
Histology (Adenoma/Well-differentiated adenocarcinoma) 3/18(14.3) 9/60(13.0) 0.883
Duaration of ESD(min) 50.3 ± 18.8 42.1 ± 14.9 0.014
Location of tumor Antrum 9 32 0.528
Angulus 7 15
Corpus 5 22
Concrurrent disease(diabetes, renal failure, cirrhosis)(+/−)(%positive) 3/18(14.3) 25/44(36.2) 0.057
Gastroprotective agent(+/−)(%positive) 5/16(23.8) 34/35(49.3) 0.039
LDA + warfarin(+/−)(%positive) 12/9(57.1) 9/60(13.0) <0.001
LDA + thienopyridine(+/−)(%positive) 3/18(14.3) 20/49(29.0) 0.176
  1. ESD endoscopic submucosal dissection, LDA low-dose aspirin.
  2. p < 0.05 vs non-bleeding. Ratios were analysed using the χ2 test.